Moneycontrol PRO

At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

Jump to
  • Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang

    Net Sales are expected to increase by 10.5 percent Y-o-Y (up 1.9 percent Q-o-Q) to Rs 2,847.5 crore, according to Nirmal Bang.

  • Alkem Laboratories reports strong numbers in Q3; highlights of analyst call

  • Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities

  • Global brokerages upgrade these 6 stocks to buy post Q4 results

  • Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities

  • Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

  • Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

  • Alkem Q4 PAT may dip 42.8% to Rs 133.6 cr: ICICI Securities

  • Alkem Labs Q3 PAT may dip 27% to Rs 210 cr: HDFC Securities

  • Alkem Q3 PAT may dip 28.5% to Rs 202.3 cr: ICICI Securities

  • See FY17 margin at 17% with downside pressure: Alkem Labs

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347